{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Foncologypodcast.simplecast.com%2Fepisodes%2Fcdk46-inhibitors-in-breast-cancer-zXtfYqrf","width":444,"version":"1.0","type":"rich","title":"CDK4/6 Inhibitors in HR-Positive/HER2-Negative Breast Cancer: Experts Answer Your Questions","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/165defb8-f7d7-44fe-a7eb-a59f2c35d334/c75a0a38-226e-4274-9a86-386e9c5352b5/100651-breast-cdk46i-3000x3000.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"<iframe src=\"https://player.simplecast.com/4378aec5-ae6f-4799-bbc2-decd09e111bc\" height=\"200\" width=\"100%\" title=\"CDK4/6 Inhibitors in HR-Positive/HER2-Negative Breast Cancer: Experts Answer Your Questions\" frameborder=\"0\" scrolling=\"no\"></iframe>","height":200,"description":"Listen to Drs William J. Gradishar, Heather McArthur, and Joanne Mortimer address key questions on the use of CDK4/6 inhibitors in HR-positive/HER2-negative breast cancer treatment. The discussion covers genomic testing options, adjuvant treatment duration, toxicity management topics, and how the available clinical data and updated guidelines influence therapeutic decisions."}